{
  "Cancer Histology Type (Ov)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20171128_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        1271, 
        1285
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20171128_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        1495, 
        1509
      ]
    }
  ], 
  "Clinical History Heading (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20171128_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        1073, 
        1096
      ]
    }
  ], 
  "Final Diagnosis Heading (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20171128_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        1165, 
        1192
      ]
    }
  ], 
  "Laterality (Ov)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20171128_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        3071, 
        3076
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20171128_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        3103, 
        3107
      ]
    }
  ], 
  "Macroscopic/Gross Description Heading (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20171128_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        553, 
        582
      ]
    }
  ], 
  "Microscopic Heading (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20171128_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        2963, 
        2998
      ]
    }
  ], 
  "Nature of Specimen Heading (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20171128_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        3040, 
        3066
      ]
    }
  ], 
  "Neoplasm Grade-Score Name (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Gemma,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        1287, 
        1294
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Gemma,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        1511, 
        1518
      ]
    }
  ], 
  "Neoplasm Score Value (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Gemma,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        1309, 
        1310
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Gemma,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        1533, 
        1534
      ]
    }
  ], 
  "Organ/Body Structure (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20171128_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        1261, 
        1270
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20171128_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        1485, 
        1494
      ]
    }
  ], 
  "Relative Location (Ov)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20171128_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        1207, 
        1235
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20171128_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        1432, 
        1459
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20171128_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        3077, 
        3099
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20171128_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        3108, 
        3130
      ]
    }
  ], 
  "Specimen Identifier (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Gemma,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        1194, 
        1195
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Gemma,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        1419, 
        1420
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Gemma,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        3068, 
        3069
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Gemma,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        3100, 
        3101
      ]
    }
  ], 
  "Supplementary Report Heading (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20171128_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        1645, 
        1677
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20171128_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        1679, 
        1694
      ]
    }
  ], 
  "__text": "MSH|^~\\&|PathSys|Associated Pathologists, LLC d/b/a PathGroup^44D1084007^CLIA|eMARCPlus|TN Cancer Registry|20170919125835||ORU^R01^ORU_R01|201709191258350001|P|2.5.1|TN||||||||VOL_V_40_ORU_R01-CCR1^NAACCR_CP\nOBR|1||17-55-004859^PathSys^44D1084007^CLIA|11529-5^SURGICAL PATH REPORT^LN|||20170828103400|||||||20170828000000|&Prostate, Needle Biopsy, Prostate, Needle Biopsy|1467452771^^^^^^MD^^CMS^D^^^NPI||||||20170829000000|||F||||||C61^Malignant neoplasm of prostate^I10~R97.20^Elevated prostate specific antigen [PSA]^I10|1285672592&&&&&&&&CMS\n\n\n\n\n\n\n\nPath report.gross description\n\nThe patient's name is \"\" identified by requisition and specimen container label. 1. Received in formalin in a container labeled with the patient's name and \"right posterior lateral base\" are 4 cores of tan and red-brown tissue 3 mm, 4 mm, 10 mm, 9 mm, all submitted in cassette 1A. 2. Received in formalin in a container labeled with the patient's name \"left post lateral base\" are 2 cores of soft tan tissue 11 mm, 12 mm, both submitted 10 mm, 9 mm, all submitted in cassette 1A. (JDM)\n\n\nPath report.relevant Hx\n\nHistory - Elevated prostate specific antigen [PSA] (R97.2) - 5.2\n\n\nPath report.final diagnosis\n\n1. Prostate, right posterior lateral base (MRI-guided biopsy):     Prostatic adenocarcinoma, Gleason's pattern 3+4=7 (15% pattern 4, grade       group 2).     7 mm of tumor occupying 50% of the tissue, 2 of 2 cores involved. 2. Prostate, left posterior lateral base (MRI-guided biopsy):     Prostatic adenocarcinoma, Gleason's pattern 3+4=7 (40% pattern 4, grade       group 2).     4 mm of tumor occupying 30% of the tissue, 2 of 2 cores involved.\n\n\nPath report.supplemental reports\n\nAddendum Report: Immunohistochemistry with appropriate controls was performed on block 1A for PTEN and ERG (TMPRSS2:ERG transformation product) in a section containing invasive carcinoma. The results are as follows: ResultsPrognostic Group PTEN intact/ERG overexpressionIntermediate  Note: Combined PTEN loss and ERG overexpression has been associated with an increased risk of early biochemical relapse following prostatectomy and higher stage disease. ERG overexpression has been associated with an increased risk of progression on active surveillance References: 1. Reid, AHM, et. al., Molecular characterization of ERG, ETV1 and PTEN gene loci identifies patients at low and high risk of death from prostate cancer. Br. J. Cancer. (2010) 102, 678-684. 2. Burg KD, et. al., ERG Protein Expression in Diagnostic Specimens Is Associated with Increased Risk of Progression During Active Surveillance for Prostate Cancer. European Urology (2014) 66(1), 851-860 3. Shah RB. Clinical applications of novel ERG immunohistochemistry in prostate cancer diagnosis and management. Adv. Anat. Pathol. (2013) 20(2):117-24 4. Nagle RB, et. al., ERG overexpression and PTEN status predict capsular penetration in prostate carcinoma. Prostate.(2013) 73(11):1233-40 ## End of auxiliary report ##\n\n\nPath report.microscopic examination\n\nMicroscopic examination is performed.\n\n\nPath report.site of origin\n\n1. Right posterior lateral base 2. Left posterior lateral base\n\n\n"
}